Percutaneous coronary intervention

OrbusNeich Achieves Record-High Revenue and Net Profit of US$154 Million and US$45.1 Million Respectively, Recommends Final Dividend Payment of HK10 cents per Share

Retrieved on: 
Thursday, March 7, 2024

-- Revenue hit record high at US$153.9 million, up 12.5% year-on-year

Key Points: 
  • -- Revenue hit record high at US$153.9 million, up 12.5% year-on-year
    -- Revenue from PCI balloons and PTA balloons grew by 12.1% and 29.0% year-on-year, respectively.
  • In particular, revenue from PCI balloons and PTA balloons grew by 12.1% and 29.0% year-on-year to US$115.4 million and US$14.7 million, respectively.
  • As at December 31, 2023, the Group was in a strong financial position with cash and bank balances amounting to US$255.8 million (2022: US$229.1 million).
  • Having considered future capital requirements, the Board has proposed a final dividend of HK10 cents per share in cash, as a token of appreciation for the continuous support of shareholders.

Saghmos Therapeutics Announces Appointment of FDA Veteran Stephen Grant, MD, as Chief Regulatory Officer

Retrieved on: 
Wednesday, February 21, 2024

Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced the appointment of Stephen Grant, MD, as Chief Regulatory Officer.

Key Points: 
  • Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced the appointment of Stephen Grant, MD, as Chief Regulatory Officer.
  • Dr. Grant was the former Deputy Director, Division of Cardiology and Nephrology at the FDA.
  • His guidance and his wealth of regulatory experience in the cardio-renal area at the FDA will tremendously benefit our mission to bring ST-62516 to patients,” said Anna Kazanchyan, MD, Founder and CEO of Saghmos.
  • ST-62516 could benefit all PCI patients, not just those with comorbidities, to reduce the threat of AKI and MACKE after PCI.

The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attack

Retrieved on: 
Wednesday, February 7, 2024

February 7, 2024, the University of Birmingham and Acticor Biotech are proud to announce the first patient treated in the LIBERATE clinical study to evaluate glenzocimab efficacy in myocardial infarction.

Key Points: 
  • February 7, 2024, the University of Birmingham and Acticor Biotech are proud to announce the first patient treated in the LIBERATE clinical study to evaluate glenzocimab efficacy in myocardial infarction.
  • In 2022, the University of Birmingham and Acticor Biotech signed a partnership agreement to evaluate glenzocimab efficacy in myocardial infarction in a new clinical trial called LIBERATE.
  • This study is exploring the potential of glenzocimab in reducing the type of blood clotting responsible for heart damage during heart attacks.
  • Birmingham Health Partners is a strategic alliance between five organisations who collaborate to bring healthcare innovations through to clinical application:

Saghmos Therapeutics Announces Notice of Allowance for Second US Patent for Phase 3-Ready Cardiorenal Metabolic Modulator ST-62516

Retrieved on: 
Wednesday, February 7, 2024

Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced a Notice of Allowance for a second US patent for its Phase 3-ready product, ST-62516 (trimetazidine), a cardiorenal metabolic modulator.

Key Points: 
  • Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced a Notice of Allowance for a second US patent for its Phase 3-ready product, ST-62516 (trimetazidine), a cardiorenal metabolic modulator.
  • "We are very pleased to announce the Notice of Allowance for our second patent, which will enhance the long-term value of ST-62516.
  • Saghmos continues to build its intellectual property estate,” commented Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics.
  • ST-62516 could benefit all PCI patients, not just those with comorbidities, to reduce the threat of AKI and MACKE after PCI.

Avenacy Announces Launch of Bivalirudin for Injection in the U.S. Market

Retrieved on: 
Monday, January 29, 2024

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Bivalirudin for Injection in the United States as a therapeutic equivalent generic for Angiomax® for Injection (bivalirudin) approved by the U.S. Food and Drug Administration.

Key Points: 
  • Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Bivalirudin for Injection in the United States as a therapeutic equivalent generic for Angiomax® for Injection (bivalirudin) approved by the U.S. Food and Drug Administration.
  • Bivalirudin for Injection is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome.
  • Avenacy will begin shipping Bivalirudin for Injection to wholesale partners this week.
  • Bivalirudin for Injection had U.S. sales of approximately $25 million for the twelve months ending in June 2023.1
    Please see link for Full Prescribing Information.

Intravascular Ultrasound (IVUS) Global Strategic Analysis Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 10, 2024

The "Intravascular Ultrasound (IVUS) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Intravascular Ultrasound (IVUS) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • This report provides an overview of Medical Ultrasound, with a specific focus on Intravascular Ultrasound (IVUS) and its applications in the medical field.
  • It begins with a general introduction to medical ultrasound and highlights the advantages of ultrasound as compared to other imaging modalities.
  • The report discusses the indications and techniques of Intravascular Ultrasound, providing a comprehensive understanding of its use in medical procedures.

Human medicines European public assessment report (EPAR): Clopidogrel Viatris (previously Clopidogrel Taw Pharma), clopidogrel, Date of authorisation: 16/10/2009, Revision: 27, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Clopidogrel Viatris (previously Clopidogrel Taw Pharma), clopidogrel, Date of authorisation: 16/10/2009, Revision: 27, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Clopidogrel Viatris (previously Clopidogrel Taw Pharma), clopidogrel, Date of authorisation: 16/10/2009, Revision: 27, Status: Authorised

OrbusNeich Acquires 84% Stake in an Indonesian Distributor for Approximately US$15 Million

Retrieved on: 
Monday, November 27, 2023

The consideration for the acquisition will be funded from the proceeds of the Group's global offering and cash generated from operations.

Key Points: 
  • The consideration for the acquisition will be funded from the proceeds of the Group's global offering and cash generated from operations.
  • PT Revass is an Indonesian company that specializes in the distribution and sale of cardiovascular intervention, neuro intervention, peripheral intervention and continuous renal replacement therapy products.
  • Its profit after tax in FY2022 amounted to IDR14.3 billion (equivalent to approximately US$920,000).
  • As of 30 June 2023, its unaudited net asset value was approximately IDR88.1 billion (equivalent to approximately US$5.7 million).

OrbusNeich Adds Drug-eluting Balloons in Product Portfolio Through Acquisition of Eucatech AG

Retrieved on: 
Thursday, November 23, 2023

Upon completion of the acquisition, Eucatech AG will become a wholly-owned subsidiary of the Group.

Key Points: 
  • Upon completion of the acquisition, Eucatech AG will become a wholly-owned subsidiary of the Group.
  • Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, "We are pleased to announce the acquisition of Eucatech AG, a company with two decades of experience and a shared mission with OrbusNeich.
  • We believe that this acquisition will enrich our product portfolio.
  • Therefore, the Group views this acquisition as a strategic move to reinforce its market presence and distribution network .

Roivios® announces final patient enrollment in feasibility trial for JuxtaFlow® Renal Assist Device (RAD)

Retrieved on: 
Monday, December 4, 2023

"When we began this feasibility trial, we anticipated the use of the JuxtaFlow RAD to be an exciting moment," said Prof. Petrovic.

Key Points: 
  • "When we began this feasibility trial, we anticipated the use of the JuxtaFlow RAD to be an exciting moment," said Prof. Petrovic.
  • Cardiac surgery-associated AKI (CSA-AKI) occurs in up to 73% of patients who have pre-existing renal insufficiency documented as part of their standard pre-surgical workup1.
  • The JuxtaFlow RAD is used in the hospital setting and is designed to enable the kidneys to function optimally and thereby improve overall patient outcomes.
  • The BIPASS-AKI feasibility trial was being conducted pursuant to the regulations of both ALIMS in Serbia and URPL in Poland.